Clinical Trial Detail

NCT ID NCT01480154
Title Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

renal cell carcinoma

prostate cancer

Advanced Solid Tumor

kidney cancer

melanoma

Therapies

Hydroxychloroquine + MK2206

Age Groups: adult senior

No variant requirements are available.